A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Exclusion Criteria

• •1. Known hypersensitivity to hypomethylating agents or Cidabenamine.
• •2. Presence of grade II or higher active acute Graft-versus-Host Disease (GVHD).
• •3. Presence of moderate or more severe chronic GVHD.
• •4. Any unstable systemic disease, including but not limited to: unstable angina, cerebrovascular accident or transient ischemic attack (within 3 months prior to screening), myocardial infarction (within 3 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] Class ≥ III), status post pacemaker implantation, severe arrhythmia requiring pharmacological treatment, hepatic, renal, or metabolic disease, or pulmonary hypertension.
• •5. Active, uncontrolled infection, evidenced by any of the following: infection-related hemodynamic instability, worsening or new-onset infectious symptoms/signs, radiologic evidence of a new infectious focus, or persistent fever without localizing symptoms/signs where infection cannot be ruled out.
• •6. Known HIV infection.
• •7. Active Hepatitis B (HBV) or active Hepatitis C (HCV) requiring antiviral therapy.
• •8. History of an autoimmune disease.
• •9. Pregnant or lactating women.
• •10. Concurrent participation in another interventional clinical trial and receiving other investigational drugs.